Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Feasibility, Safety, Initial Efficacy and Clinical Usability of FuseX Anti-Adhesion System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03820713
Recruitment Status : Completed
First Posted : January 29, 2019
Last Update Posted : July 23, 2020
Sponsor:
Information provided by (Responsible Party):
Eio Biomedical Ltd.

Brief Summary:
Evaluation of the feasibility, safety, initial efficacy and usability of FuseX Anti-Adhesion system toward further studies that will be powered to proved its safety and efficacy. In addition, this initial study will serve to yield blood bank and surgeon feedback towards improving the system.

Condition or disease Intervention/treatment Phase
Reduction of Postoperative Adhesions Procedure: Concentrate of plasma coagulation factors Procedure: 0.9% saline Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, randomized, double blinded, parallel, controlled, two-arm, two-center
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Prospective, Randomized, Double Blinded, Parallel, Controlled, Two-arm, Two-center Evaluation of the Feasibility, Safety, Initial Efficacy and Clinical Usability of FuseX Anti-Adhesion System
Actual Study Start Date : May 9, 2018
Actual Primary Completion Date : July 15, 2020
Actual Study Completion Date : July 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Adhesions

Arm Intervention/treatment
Experimental: Investigational arm
Treatment group receives a concentrate of coagulation factors. The device concentrates coagulation factors from donor plasma; the concentrate is applied to the surgical site intended to reduce the incidence, extent and severity of postoperative adhesions.
Procedure: Concentrate of plasma coagulation factors
The plasma concentrate of coagulation factors is applied to the surgical site.

Placebo Comparator: Control arm
Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
Procedure: 0.9% saline
Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.




Primary Outcome Measures :
  1. Treatment-emergent adverse event incidence [ Time Frame: Within 30 days from the first surgery ]
    Incidence of adverse events related to treatment requiring any invasive procedure in the test group (who used blood plasma concentrate prepared using FuseX Anti-Adhesion System) compared to control group (who used normal saline processed by the same FuseX Anti-Adhesion System).

  2. Overall adverse event incidence [ Time Frame: Until the second surgery but not longer than 7 months ]
    Overall adverse event incidence will be evaluated by the presence and severity of adverse events and serious adverse events in the test group (who used blood plasma concentrate prepared using FuseX Anti-Adhesion System) vs. control group (who used normal saline processed by the same FuseX Anti-Adhesion System).

  3. Severity of new formed adhesions in the target region [ Time Frame: Through study completion, an average of 1 year ]
    Severity of new formed adhesions having its source in the target region will be assessed by a blinded surgeon during the second surgery by grading the adhesion severity for each region on a scale from 0 (no adhesions) to 3 (strong vascularized adhesions that require sharp dissection and cannot be separated without tissue damage). The peritoneal cavity will be divided into 9 separate scoring regions. A peritoneal adhesion index (PAI) (sum of scores for all the regions) will be calculated per each patient.

  4. Usability as assessed by Surgeon questionnaire [ Time Frame: Through study completion, an average of 1 year ]
    a. Ease of application will be scored on a 5-point Likert scale (1 = very hard to 5 = very easy). b. Percentage of coverage the entire defined surgical field. c. mL of the materials used

  5. Usability as assessed by Operator questionnaire [ Time Frame: Through study completion, an average of 1 year ]
    a. Ease of device use will be scored on a 5-point Likert scale (1 = very hard to 5 = very easy). b. Device operation time


Secondary Outcome Measures :
  1. Incidence of general surgical complications; incidence of minor adverse events [ Time Frame: Until the second surgery but not longer than 7 months ]

    Incidence of general surgical complications including but not limited to:

    • Septic shock, cardiovascular events, respiratory tract infections and pulmonary atelectasis, urinary tract infections, thromboembolic events
    • Superficial Surgical Site Infections (SSI) - soft tissue infection, cellulitis, incisional abscess, wound dehiscence
    • Deep SSI - abdominal abscess, pelvic abscess, peritonitis. Incidence of minor adverse events such as nausea, vomiting, abdominal pain, ileus, allergic reactions

  2. Usability of the device Instructions for Use (questionnaire) [ Time Frame: Through study completion, an average of 1 year ]
    Usability of the device user manual will be scored on a 5-point Likert scale (1 = very hard to 5 = very easy).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

PREOPERATIVE INCLUSION

Preoperatively the patient must:

  1. Understand and be able to follow the requirements of the protocol including signing and dating an Ethics Committee approved Informed Consent prior to undergoing any protocol related procedures
  2. Patients undergoing any of the above procedures
  3. Male or female subjects > 18 years of age
  4. Subjects for whom a second abdominal surgery is planned within less than 12 months of the first surgical procedure
  5. BMI<40

INTRAOPERATIVE INCLUSION

During surgery the patient must require having one of the following surgeries performed on their person:

  1. Planned or emergency colonic resection surgery with temporary stoma creation due to colonic perforation, acute diverticulitis or colonic obstruction.
  2. Surgery for low rectal cancer - low anterior resection. This surgery includes resection of lower part of rectum, colo-anal anastomosis and protective ileostomy creation. Usually patient undergo second stage procedure closure of ileostomy in 1-3 months.
  3. Total proctocolectomy and a pelvic pouch with diverting ileostomy in cases of surgery for Ulcerative colitis. In this kind of surgery there is the intention to close the temporary ileostomy in 1-3 months.
  4. Creation of stoma due to infectious process or trauma in the peritoneum (such as Fournier gangrene, laceration of rectum, etc.)

Exclusion Criteria

PREOPERATIVE EXCLUSION

Preoperatively a patient must not:

  1. be unable to give their own written informed consent,
  2. be currently enrolled in another clinical study with drug or device related to adhesions or has participated in such a study within the last 30 days,
  3. have received or is expected to receive any other investigational product or technique belonging to the group of hemostats, adhesion reduction devices or other products, meshes, or other types of implants in the abdominal cavity within 30 days prior to or during enrolment,
  4. subjects who have received or will receive (approximately within the next eight months) abdominal/pelvic irradiation for reasons other than rectal carcinoma.
  5. BMI≥40
  6. Subjects who have received selective factor Xa inhibitors and/or direct thrombin inhibitors within 24 hours prior to surgery.
  7. Patients taking immune system suppressants deemed by the surgeon to interfere with wound healing, Patients taking daily doses of corticosteroids exceeding 20mg within the prior 30 days are to be excluded. Patients requiring perioperative corticosteroid supplementation are not to be excluded.
  8. Patients with a known history of severe multiple drug allergies
  9. Patients who have a life expectancy of less than 6 months because of a medical condition or disease state
  10. Any patient with a medical condition or other serious condition which will interfere with compliance and/or ability to complete this study protocol or who in the opinion of the investigator would not be a good candidate for enrollment

INTRAOPERATIVE EXCLUSION

  1. Patients for whom it is known, prior to the initial procedure, that loop ileostomy or colostomy closure is not feasible for any reason
  2. Patients with peritoneal carcinomatosis
  3. Patients with endometriosis
  4. Use of hernia mesh in the first surgery.
  5. Subjects treated with hemostatic agents in which the sealant remains in the patient's body (e.g. Fibrin sealant).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03820713


Locations
Layout table for location information
Lithuania
Kaunas Clinical Hospital
Kaunas, Lithuania, LT-47144
Hospital of Lithuanian University of Health Sciences Kauno Klinikos
Kaunas, Lithuania, LT-50009
Sponsors and Collaborators
Eio Biomedical Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Rafael Miller, MD EIO Biomedical Ltd., Medical Adviser
Layout table for additonal information
Responsible Party: Eio Biomedical Ltd.
ClinicalTrials.gov Identifier: NCT03820713    
Other Study ID Numbers: AOS-CL1000-02
CL-PL-057-01 ( Other Identifier: EIO Biomedical Ltd. )
First Posted: January 29, 2019    Key Record Dates
Last Update Posted: July 23, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tissue Adhesions
Cicatrix
Fibrosis
Pathologic Processes